P920: EFFECTIVENESS AND SAFETY OF SELINEXOR-BASED REGIMEN IN THE TREATMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A MULTICENTER REAL-WORLD STUDY FROM CHINA

KUANG Lifen,FANG Baijun,CHEN Wenming,LIU Aijun,LI Chunrui,BAO Li,FU Chengcheng,CHEN Jiao,LI Hui,PANG Ying,LIAO Aijun,LIANG Yang,WEI Yongqiang,LI Juan
DOI: https://doi.org/10.1097/01.hs9.0000846548.89204.ce
2022-01-01
HemaSphere
Abstract:Background: Background: Selinexor is the first approved oral selective nuclear exportin inhibitor. Clinical trials have shown that selinexor-based regimens improved the survival of RRMM patients. However, there are limited reports on the effectiveness and safety of selinexor in the real world. Aims: Aims: To evaluate the effectiveness and safety of selinexor-based regimens in the treatment of patients with relapsed and refractory multiple myeloma (RRMM) in real world settings. Methods: Methods: The clinical data of 53 patients with RRMM who were treated with selinexor-based regimens in 11 centers in China from July 2020 to December 2021 were retrospectively analyzed, and the response, survival and side effects were evaluated. Results: Results: The median age of the 53 patients with RRMM at the time of treatment with the selinexor-based
What problem does this paper attempt to address?